New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs

Cellular and Molecular Life Sciences

Volumn 61, Issue 9, 2004, Pages 1042-1068

  Schally, A V ^a,b   Szepeshazi, K ^a,b   Nagy, A ^a,b   Comaru Schally, A M ^a,b   Halmos, G ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bombesin GRP antagonists; Gastrin; Gastrin releasing peptide (GRP); GH RH antagonists; Somatostatin analogs; Targeted cytotoxic peptides

Indexed keywords

2 PYRROLINODOXORUBICIN; ANALGESIC AGENT; ANGIOPEPTIN; ANTIANDROGEN; ANTIESTROGEN; BOMBESIN; BOMBESIN ANTAGONIST; BOMBESIN DERIVATIVE; BUSERELIN; CYPROTERONE ACETATE; CYTOTOXIC AGENT; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; GASTRIN; GASTRIN RELEASING PEPTIDE; GONADORELIN DERIVATIVE; GOSERELIN; HORMONE ANTAGONIST; NEUROMEDIN B; OCTREOTIDE; RC 3095; RC 3940; SOMATOMEDIN; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE;

CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; DISEASE COURSE; GALLSTONE; HORMONAL THERAPY; HUMAN; ISOTOPE LABELING; METASTASIS; MUSCLE CRAMP; NEOPLASM; NONHUMAN; PANCREAS CANCER; QUALITY OF LIFE; REVIEW; SCINTIGRAPHY; SIDE EFFECT; STOMACH CANCER; TUMOR GROWTH; TUMOR LOCALIZATION;

ANIMALS; BOMBESIN; COLONIC NEOPLASMS; HUMANS; OLIGOPEPTIDES; PANCREATIC NEOPLASMS; SOMATOSTATIN; STOMACH NEOPLASMS;

MAMMALIA;

EID: 2442604328     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-004-3434-3     Document Type: Review

References (283)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E. and Thun M. J. (2003). Cancer statistics, 2003. CA Cancer J. Clin. 53: 5-26
2. Bray F., Sankila R., Ferlay J. and Parkin D. M. (2002) Estimates of cancer incidence and mortality in Europe in 1995. Eur. J. Cancer. 38: 99-166
3. Parkin D. M., Pisani P. and Ferlay J. (1999) Global cancer statistics. CA Cancer J. Clin. 49: 33-64
4. Kopchick J. J., List E. O., Kohn D. T., Keidan G. M. O., Qiu L. and Okada S. (2002) Perspective: proteomics - see 'spots' run. Endocrinology 143: 1990-1994
5. Schally A. V., Comaru-Schally A. M., Nagy A., Kovacs M., Szepeshazi K., Plonowski A. et al. (2001) Hypothalamic hormones and cancer. Front. Neuroendocrinol. 22: 248-291
6. Schally A. V. and Nagy A. (2003) New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci. 72: 2305-2320
7. Spindel E. R., Giladi E., Segerson T. P. and Nagalla S. (1993) Bombesin-like peptides: of ligands and receptors. Recent Prog. Horm. Res. 48: 365-391
8. Sunday M. E., Kaplan L. M., Motoyama E., Chin W. W. and Spindel E. R. (1988) Gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease. Lab. Invest. 59: 5-24
9. Wang Q. J., Knezetic J. A., Schally A. V., Pour P. M. and Adrian T. E. (1996) Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway. Int. J. Cancer 68: 528-534.
10. Frohman L. A. and Szabo M. (1981) Ectopic production of growth hormone-releasing factor by carcinoid and pancreatic islet tumors associated with acromegaly. Prog. Clin. Biol. Res. 74: 259-271
11. Reubi J.-C. and Laissue J. A. (1995) Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol. Sci. 16: 110-115
12. th ed, chap. 61, pp. 911-926, Kufe D. W., Pollock R. E., Weichselbaum R. R., Bast R. C. Jr, Gansler T. S., Holland J. F. et al. (eds), B. C. Dekker, Hamilton, Ontario
13. Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier J. et al. (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179: 77-79
14. Schally A. V. (1988) Oncological applications of somatostatin analogs. Cancer Res. 48: 6977-6985
15. Konturek S. J., Bilski J., Jaworek J., Tasler J. and Schally A. V. (1988) Comparison of somatostatin and its highly potent hexa- and octapeptide analogs on exocrine and endocrine pancreatic secretion. Proc. Soc. Exp. Biol. Med. 187: 241-249
16. Bauer W., Briner U., Doepfner W., Haller R., Huguenin R., Marbach P. et al. (1982) SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 31: 1133-1140
17. Cai R-Z., Szoke B., Lu R., Fu D., Redding T. W. and Schally A. V. (1986) Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc. Natl. Acad. Sci. USA 83: 1896-1900
18. Patel Y. C. (1997) Molecular pharmacology of somatostatin receptor subtypes. J. Endocrinol. Invest. 20: 348-367
19. Reisine T. and Bell G. I. (1995) Molecular biology of somatostatin receptors. Endocr. Rev. 16: 427-442
20. 3]octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20: 716-731
21. Liebow C., Reilly C., Serrano M. and Schally A. V. (1989) Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc. Natl. Acad. Sci. USA 86: 2003-2007
22. Buscail L., Delesque N., Esteve J.-P., Saint-Laurent N., Prats H., Clerc P. et al. (1994) Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc. Natl. Acad. Sci. USA 91: 2315-2319
23. Buscail L., Esteve J. P., Saint-Laurent N., Bertrand V., Reisine T., O'Carroll A. M. et al. (1995) Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by SSTR2 and SSTR5 somatostatin receptor subtypes through different mechanisms. Proc. Natl. Acad. Sci. USA 92: 1580-1584
24. Bousquet C., Puente E., Buscail L., Vaysse N. and Susini C. (2001) Antiproliferative effect of somatostatin and analogs. Chemotherapy 47: 30-39
25. Sharma K., Patel Y. C. and Srikant C. B. (1999) C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol. Endocrinol. 13: 82-90
26. Florio T., Yao H., Carey K. D., Dillon T. J. and Stork P. J. S. (1999) Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol. Endocrinol. 13: 24-37
27. Hofland L. J. and Lamberts S. W. (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 24: 28-47
28. Csaba Z. and Dournaud P. (2001) Cellular biology of somatostatin receptors. Neuropeptides 35: 1-23
29. De la Torre N. G., Wass J. A. H. and Turner H. E. (2002) Antiangiogenic effects of somatostatin analogues. Clin. Endocrinol. 57: 425-441
30. Lamberts S. W., de Herder W. W. and Hofland L. J. (2002) Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol. Metab. 13: 451-457
31. th Edn, chapt. 89, pp. 1275-1323, Kufe D. W., Pollock R. E., Weichselbaum R. R., Bast R. C. Jr, Gansler T. S., Holland J. F. et al. (eds) B. C. Dekker, Hamilton, Ontario
32. Kouroumalis E., Skordilis P., Thermos K., Vasilaki A., Moschandrea J. and Manousos O. N. (1998) Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42: 442-447
33. Bruns C., Lewis I., Briner U., Meno-Tetang G. and Weckbecker G. (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol. 146: 707-716
34. 3 selectivity. J. Med. Chem. 44: 2990-3000
35. Reubi J. C., Schaer J. C., Wenger S., Hoeger C., Erchegyi J., Waser B. et al. (2000) SST3-selective potent peptidic somatostatin receptor antagonists. Proc. Natl. Acad. Sci. USA 97: 13973-13978
36. 111In- pentetreotide: initial observations and future directions. Cancer J. Sci. Am. 4: 94-102
37. Kwekkeboom D. J., Krenning E. P., Bakker W. H., Oei H. Y., Kooij P. P. M. and Lamberts S. W. J. (1993) Somatostatin analogue scintigraphy in carcinoid tumors. Eur. J. Nucl. Med. 20: 283-292
38. Raderer M., Pangerl T., Leimer M., Valencak J., Kurtaran A., Hamilton G. et al. (1998) Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo. J. Natl. Cancer Inst. 90: 1666-1668
39. Heppeler A., Froidevaux S., Eberle A. N. and Maecke H. R. (2000) Receptor targeting for tumor localisation and therapy with radiopeptides. Curr. Med. Chem. 7: 971-994
40. Reubi J. C., Schär J. C., Waser B., Wenger S., Heppeler A., Schmitt J. S. et al. (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27: 273-282
41. 3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int. J. Cancer 92: 628-633
42. Buscail L., Saint-Laurent N., Chastre E., Vaillant J. C., Gespach C., Capella G. et al. (1996) Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res. 56: 1823-1827
43. Laws S. A. M., Gough A. C., Evans A. A., Bains M. A. and Primrose J. N. (1997) Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae. Br. J. Cancer 75: 360-366
44. Pinzani P., Orlando C., Raggi C. C., Distante V., Valanzano R., Tricarico C. et al. (2001) Type-2 somatostatin receptor mRNA levels in breast and colon cancer determined by a quantitative RT-PCR assay based on dual label fluorogenic probe and the TaqMan technology. Regul. Pept. 99: 79-86
45. Radulovic S., Milovanovic S., Cai R. Z. and Schally A. V. (1992) The binding of bombesin and somatostatin and their analogs to human colon cancers. Proc. Soc. Exp. Biol. Med. 200: 394-401
46. Reubi J. C., Waser B., Schmassmann A. and Laissue J. A. (1999) Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: where are they really located? Int. J. Cancer 81: 376-386
47. Virgolini I., Szilvasi I., Kurtaran A., Angelberger P., Raderer M., Havlik E. et al. (1998) Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J. Nucl. Med. 39: 1928-1936
48. Miller G. V., Farmery S. M., Woodhouse L. F. and Primrose J. N. (1992) Somatostatin binding in normal and malignant human gastrointestinal mucosa. Br. J. Cancer 66: 391-395
49. Halmos G., Schally A. V., Sun B., Davis R., Bostwick D. G. and Plonowski A. (2000) High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J. Clin. Endocrinol. Metab. 85: 2564-2571
50. Halmos G., Sun B., Schally A. V., Hebert F. and Nagy A. (2000) Human ovarian cancers express somatostatin receptors. J. Clin. Endocrinol. Metab. 85: 3509-3512
51. Nagy A., Schally A. V., Halmos G., Armatis P., Cai R.-Z., Csernus V. et al. (1998) Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc. Natl. Acad. Sci. USA 95: 1794-1799
52. Nagy A. and Schally A. V. (2001) Targeted cytotoxic somatostatin analogs: a modern approach to the therapy of various cancers. Drugs of the Future 26: 261-270
53. Anastasi A., Erspamer V. and Bucci M. (1971) Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia 27: 166-167
54. McDonald T. J., Jornvall H., Nilsson G., Vagne M., Ghatei M, Bloom S. R. et al. (1979) Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. Biochem. Biophys. Res. Commun. 90: 227-233
55. Minamino N., Kangawa K. and Matsuo H. (1984) Neuromedin B is a major bombesin-like peptide in rat brain: regional distribution of neuromedin B and neuromedin C in rat brain, pituitary and spinal cord. Biochem. Biophys. Res. Commun. 124: 925-932
56. Cuttitta F., Carney D. N., Mulshine J., Moody T. W., Fedorko J., Fischler A. et al. (1985) Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer. Nature 316: 823-826
57. Carroll R. E., Matkowskyj K. A., Tretiakova M. S., Battey J. F. and Benya R. V. (2000) Gastrin-releasing peptide is a mitogen and a morphogen in murine colon cancer. Cell Growth Differ. 11: 385-393
58. Jensen J. A., Carroll R. E. and Benya R. V. (2001) The case for gastrin-releasing peptide acting as a morphogen when it and its receptor are aberrantly expressed in cancer. Peptides 22: 689-699
59. Chave H. S., Gough A. C., Palmer K., Preston S. R. and Primrose J. N. (2000) Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa. Br. J. Cancer 82: 124-130
60. 13]bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4). Proc. Natl. Acad. Sci. USA 92: 6205-6209
61. Fathi Z., Corjay M. H., Shapira H., Wada E., Benya R., Jensen R. et al. (1993) BRS-3: a novel bombesin receptor subtype selectively expressed in testis and lung carcinoma cells. J. Biol. Chem. 268: 5979-5984
62. 14] bombesin(6-14). Clin. Cancer Res. 8: 1139-46
63. 2 or its derivatives. Proc. Natl. Acad. Sci. USA 91: 12664-12668
64. Coy D. H., Taylor J. E., Jiang N. Y., Kim S. H., Wang L. H., Huang S. C. et al. (1989) Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity. J. Biol. Chem. 264: 14691-14697
65. Langdon S., Sethi T., Ritchie A., Muir M., Smyth J. and Rozengurt E. (1992) Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res. 52: 4554-4557
66. Moody T. W., Chan D., Fahrenkrug J. and Jensen R. T. (2003) Neuropeptides as autocrine growth factors in cancer cells. Curr. Pharm. Des. 9: 495-509
67. Moody T. W. and Jensen R. T. (1998) Bombesin receptor antagonists. Drugs of the Future 23: 1305-1315
68. Heasley L. E. (2001) Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 20: 1563-1569
69. Szepeshazi K., Halmos G., Schally A. V., Arencibia J. M., Groot K., Vadillo-Buenfil M. et al. (1999) Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogues. J. Cancer Res. Clin. Oncol. 125: 444-452
70. Markwalder R. and Reubi J. C. (1999) Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 59: 1152-1159
71. 2]: syntheses, radiolabeling and in vitro/in vivo GRP receptor targeting studies. Anticancer Res. 23: 63-70
72. Scopinaro F., Varvarigou A. D., Ussof W., De Vincentis G., Sourlingas T. G., Evangelatos G. P. et al. (2002) Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. Cancer Biother. Radiopharm. 17: 327-335
73. Nagy A., Armatis P., Cai R.-Z., Szepeshazi K., Halmos G. and Schally A. V. (1997) Design, synthesis and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc. Natl. Acad. Sci. USA 94: 652-656
74. Bagnato A., Moretti C., Ohnishi J., Frajese G. and Catt K. J. (1992) Expression of the growth hormone-releasing hormone gene and its peptide product in the rat ovary. Endocrinology 130: 1097-1102
75. Rivier J., Spiess J., Thorner M. and Vale W. (1982) Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature 300: 276-278
76. Busto R., Schally A. V., Varga J. L., Garcia-Fernandez M. O., Groot K., Armatis P. et al. (2002) The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas Proc. Natl. Acad. Sci. USA 99: 11866-11871
77. Rekasi Z., Czompoly T., Schally A. V. and Halmos G. (2000) Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc. Natl. Acad. Sci. USA 97: 10561-10566
78. Halmos G., Schally A. V., Varga J. L., Plonowski A., Rekasi Z. and Czompoly T. (2000) Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 97: 10555-10560
79. 2 as a GRF antagonist on membranes. Endocrinology 117: 1759-1764
80. Zarandi M., Kovacs M., Horvath J., Toth K., Halmos G., Groot K. et al. (1997) Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH). Peptides 18: 423-430
81. Varga J. L., Schally A. V., Csernus V. J., Zarandi M., Halmos G. and Rekasi Z. (1999) Synthesis and biological evaluation of antagonists of GH-RH with high and protracted in vivo activities. Proc. Natl. Acad. Sci. USA 96: 692-697
82. Schally A. V and Varga J. L. (1999) Antagonistic analogs of growth hormone-releasing hormone: new potential antitumor agents. Trends Endocrinol. Metab. 10: 383-391
83. Ma J., Pollak M. N., Giovannucci E., Chan J. M., Tao Y., Hennekens C. H. et al. (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (TGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. 91: 620-625
84. Reinmuth N., Fan F., Liu W., Parikh A. A., Stoeltzing O., Jung Y. D et al. (2002) Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest. 82: 1377-1389
85. Jaffe C. A., DeMott-Friberg R., Frohman L. A. and Barkan A. L. (1997) Suppression of growth hormone (GH) hypersecretion due to ectopic GH-releasing hormone (GHRH) by a selective GHRH antagonist. J. Clin. Endocrinol. Metab. 82: 634-637
86. Kojima M., Hosod H., Date Y., Nakazato M., Matsuo H. and Kangawa K. (1999) Ghrelin is a growth hormone releasing acylated peptide from stomach. Nature 402: 656-660
87. Gnanapavan S., Kola B., Bustin S. A., Morris D. G., McGee P., Fairclough P. et al. (2002) The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J. Clin. Endocrinol. Metab. 87: 2988-2991
88. Papotti M., Cassoni P., Volante M., Deghenghi R., Muccioli G. and Ghigo E. (2001) Ghrelin-producing endocrine tumors of the stomach and intestine. J. Clin. Endocrinol. Metab. 86: 5052-5059
89. Cassoni P., Papotti M., Ghe C., Catapano F., Sapimo A., Graziani A. et al. (2001) Identification, characterization and biological activity of specific receptors for natural (Ghrelin) and synthetic growth hormone secratagogues and analogs in human breast carcinomas and cell lines. J. Clin. Endocrinol. Metab. 86: 1738-1745
90. Volante M., Allia E., Gugliotta P., Funaro A., Broglio F, Deghenghi R. et al. (2002) Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J. Clin. Endocrinol. Metab. 87: 1300-1308
91. Corbetta S., Peracchi M., Cappiello V., Lania A., Lauri E., Vago L. et al. (2003) Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma. J. Clin. Endocrinol. Metab. 88: 3117-3120
92. Gregory H., Hardy P. M., Jones D. S., Kenner G. W. and Sheppard R. C. (1964) The antral hormone gastrin: structure of gastrin. Nature 204: 931-933
93. Yalow R. S. and Berson S. A. (1970) Size and charge distinctions between endogenous human plasma gastrin in peripheral blood and heptadecapeptide gastrins. Gastroenterology 58: 609-615
94. Thompson J. C. and Marx M. (1984) Gastrointestinal hormones. In: Current Problems in Surgery, pp. 1-80, Ravitch M. M. (ed.), Year Book Medical Publishers, Chicago, IL
95. Koh T. J. and Chen D. (2000) Gastrin as a growth factor in the gastrointestinal tract. Regul. Pept. 93: 37-44
96. Silen M. L. and Gardner J. D. (1993) Gastrointestinal peptides and cancer. Trends Endocrinol. Metab. 4: 131-135
97. Johnson L. R. (1988) Regulation of gastrointestinal mucosal growth. Physiol. Rev. 68: 456-502
98. Mutt V. and Jorpes J. E. (1971) Hormonal polypeptides of the upper intestine. Biochem. J. 125: 57-58
99. Rehfeld J. F., Holst J. J. and Lindkaer Jensen S. (1982) The molecular nature of vascularly released cholecystokinin from the isolated perfused porcine duodenum. Regul. Pept. 3: 15-28
100. Rayford P. L., Miller T. A. and Thompson J. C. (1976) Secretin, cholecystokinin and newer gastrointestinal hormones. N. Engl. J. Med. 294: 1093-1101, 1157-1164
101. Morley J. E. (1982) The ascent of cholecystokinin (CCK) - from gut to brain. Life Sci. 30: 479-493
102. Palmer Smith J., Solomon T. E., Bagheri S. and Kramer S. (1990) Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. Dig. Dis. Sci. 35: 1377-1384
103. Howatson A. G. (1986) Pancreatic carcinogenesis - the potential of cholecystokinin as a co-carcinogen in the hamster-nitrosamine model. Adv. Exp. Med. Biol. 199: 109-121
104. Bayliss W. M. and Starling E. H. (1902) The mechanisms of pancreatic secretion. J. Physiol. 28: 325-353
105. Mutt V., Magnusson S., Jorpes J. E. and Dahl E. (1965) Structure of porcine secretin. I. Degradation with trypsin and thrombin, sequence of the tryptic peptides. The C-Terminal Residue Biochemistry 4: 2358-2362
106. Chey W. Y. and Konturek S. J. (1982) Plasma secretin and pancreatic secretion in response to liver extract meal with varied pH and exogenous secretin in the dog. J. Physiol. 324: 263-272
107. Said S. I. and Mutt V. (1972) Isolation from porcine-intestinal wall of a vasoactive octacosapeptide related to secretin and to glucagon. Eur. J. Biochem. 28: 199-204
108. Lauffer J. M., Modlin I. M. and Tang L. H. (1999) Biological relevance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the gastrointestinal tract. Regul. Pept. 84: 1-12
109. Said S. I. (1991) Vasoactive intestinal polypeptide; biologic role in health and disease. Trend Endocrinol. Metab. 2: 107-112
110. Reubi J. C., Läderach U., Waser B., Gebbers J. O., Robberecht R and Laissue J. A. (2000) Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res. 60: 3105-3112
111. Moody T. W., Zia F., Draoui M., Brenneman D. E., Fridkin M., Davidson A. et al. (1993) A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc. Natl. Acad. Sci. USA 90: 4345-4349
112. Moody T. W., Hill J. M. and Jensen R. T. (2003) VIP as a trophic factor in the CNS and cancer cells. Peptides 24: 163-177
113. Maruno K., Absood A. and Said S. I. (1998) Vasoactive intestinal peptide inhibits human small-cell lung cancer proliferation in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95: 14373-17378
114. Larsson L.-I., Sundler F. and Hakanson R. (1976) Pancreatic polypeptide - a postulated new hormone: identification of its cellular storage site by light and electron microscopic immunocytochemistry. Diabetologia 12: 322-326
115. Redfern J. S. and O'Dorisio T. M. (1993) Therapeutic uses of gastrointestinal peptides. Endocrinol. Metab. Clin. North Am. 22: 845-873
116. Fuchs C. S. and Mayer R. J. (1995) Gastric carcinoma. N. Engl. J. Med. 333: 32-41
117. Correa P. and Shiao Y.-H. (1994) Phenotypic and genotypic events in gastric carcinogenesis. Cancer Res. 54 (Suppl.): 1941s-1943s
118. Lauren P. (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol. Microbiol. Scand. 64: 31-49
119. Werner M., Becker K. F., Keller G. and Höfler H. (2001) Gastric adenocarcinoma: pathomorphology and molecular pathology. J. Cancer Res. Clin. Oncol. 127: 207-216
120. Ming S. (1998) Cellular and molecular pathology of gastric carcinoma and precursor lesions: a critical review. Gastric Cancer 1: 31-50
121. Leung S. Y., Chen X., Chu K. M., Yuen S. T., Mathy J., Ji J. et al. (2002) Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. Proc. Natl. Acad. Sci. USA 99: 16203-16208
122. Parsonnet J., Friedman G. D., Vandersteen D. P., Chang Y., Vogelman J. H., Orentreich N. et al. (1991) Helicobacter pylori infection and the risk of gastric carcinoma. N. Engl. J. Med. 325: 1127-1131
123. Icli F., Celik I., Aykan F., Uner A., Demirkazik A., Ozet A. et al. (1998) A randomized Phase III trial of etoposide, epirubicin and cisplatin versus 5-fluorouracil, epirubicin and cisplatin in the treatment of patients with advanced gastric carcinoma. Cancer 83: 2475-2480
124. Meyerhardt J. A. and Fuchs C. S. (2002) Chemotherapy options for gastric cancer. Semin. Radiat. Oncol. 12: 176-186
125. Watson S. A., Durrant L.G., Crosbie J. D. and Morris D. L. (1989) The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin. Int. J. Cancer 43: 692-696
126. Watson S., Durrant L. and Morris D. (1989) Gastrin: growth enhancing effects on human gastric and colonic tumour cells. Br. J. Cancer 59: 554-558
127. Nagata A., Ito M., Iwata N., Kuno J., Takano H., Minowa O. et al. (1996) G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc. Natl. Acad. Sci. USA 93: 11825-11830
128. Varro A., Noble P. J., Wroblewski L. E., Bishop L. and Dockray G. J. (2002) Gastrin-cholecystokinin-B receptor expression in AGS cells is associated with direct inhibition and indirect stimulation of cell proliferation via paracrine activation of the epidermal growth factor receptor. Gut 50: 827-833
129. Durrant L. G., Watson S. A., Hall A. and Morris D. L. (1991) Co-stimulation of gastrointestinal tumour cell growth by gastrin, transforming growth factor alpha and insulin like growth factor-I. Br. J. Cancer 63: 67-70
130. Tsigris C., Karayiannakis A. J., Syrigos K. N., Zbar A., Diamantis T., Kalahanis N. et al. (2002) Clinical significance of soluble c-erbB-2 levels in the serum and urine of patients with gastric cancer. Anticancer Res. 22: 3061-3066
131. Takehana T., Kunitomo K., Kono K., Kitahara F., Iizuka H., Matsumoto Y. et al. (2002) Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immunosorbent assay. Int. J. Cancer 98: 833-837
132. Ross J. S. and McKenna B. J. (2001) The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 19: 554-568
133. Tian X., Song S., Wu J., Meng L., Dong Z. and Shou C. (2001) Vascular endothelial growth factor: acting as an autocrine growth factor for human gastric adenocarcinoma cell MGC803. Biochem. Biophys. Res. Commun. 286: 505-512
134. Pinski J., Halmos G., Yano T., Szepeshazi K., Qin Y., Ertl T. et al. (1994) Inhibition of growth of MKN45 human gastric carcinoma xenografts in nude mice by treatment with bombesin/gastrin releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160. Int. J. Cancer 57: 574-580
135. 2 prostaglandin enprostil, and the somatostatin analogue SMS 201 995, on the growth of a human gastric cell line, MKN45G. Int. J. Cancer 45: 90-94
136. Preston S. R., Woodhouse L. F., Jones-Blackett S., Wyatt J. I. and Primrose J. N. (1993) High affinity binding sites for gastrin releasing peptide on human gastric cancer and Menetrier's mucosa. Cancer Res. 53: 5090-5092
137. Qin Y., Halmos G., Cai R.-Z., Szoke B., Ertl T. and Schally A. V. (1994) Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors. J. Cancer Res. Clin. Oncol. 120: 519-528
138. Szepeshazi K., Schally A. V., Nagy A., Wagner B. W., Bajo A. M. and Halmos G. (2003) Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer 98: 1401-1410
139. Virgolini I., Raderer M., Kurtaran A., Angelberger P., Banyai S., Yang Q. et al. (1994) Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med. 331: 1116-1121
140. Ron E., Gridley G., Hrubec Z., Page W., Arora S. and Fraumeni J. F. Jr (1991) Acromegaly and gastrointestinal cancer. Cancer 68: 1673-1677
141. Cascinu S., Del Ferro E. and Catalano G. (1995) A randomized trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Br. J. Cancer 71: 97-101
142. Befon S., Mystakidou K., Lyra M., Tubanakis N. and Vlahos L. (2000) Continuous subcutaneous octreotide in gastrointestinal cancer patients: pain control and beta-endorphin levels. Anticancer Res. 20: 4039-4046
143. Levin B., Brooks D., Smith R. A. and Stone A. (2003) Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA cancer J. Clin. 53: 44-55
144. Labianca R., Pessi M. A. and Zamparelli G. (1997) Treatment of colorectal cancer. Current guidelines and future prospects for drug therapy. Drugs 53: 593-607
145. Magnuson B. A., Raju R. V., Moyana T. N. and Sharma R. K. (1995) Increased N-myristoyl-transferase activity observed in rat and human colonic tumors. J. Natl. Cancer Inst. 87: 1630-1635
146. Moertel C. G., Fleming T. R., MacDonald J. S., Haller D. G., Laurie J. A., Goodman P. J. et al. (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322: 352-358
147. Fernando N. H. and Hurwitz H. I. (2003) Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin. Oncol. 30: 39-50
148. McCarthy M. (2003) Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 361: 1959
149. Rosen L. S. (2002) Biologic approaches to the treatment of gastrointestinal malignancy. Curr. Opin. Oncol. 14: 431-438
150. Wallace-Brodeur R. R. and Lowe S. W. (1999) Clinical implications of p53 mutations. Cell. Mol. Life Sci. 55: 64-75
151. WAF1/CIP1 via C/EBP. Nat. Med. 3: 1233-1241
152. Pollak M. N., Perdue J. F., Margolese R. G., Baer K. and Richard M. (1987) Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett. 38: 223-230
153. Lahm H., Suardet L., Laurent P. L., Fischer J. R., Ceyhan A., Givel J. C. et al. (1992) Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor alpha. Br. J. Cancer 65: 341-346
154. Jenkins P. J., Frajese V., Jones A. M., Camacho-Hubner C., Lowe D. G., Fairclough P. D. et al. (2000) Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J. Clin. Endocrinol. Metab. 85: 3218-3221
155. Sandhu M. S., Dunger D. B. and Giovannucci E. L. (2002) Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions and colorectal cancer. J. Natl. Cancer Inst. 94: 972-980
156. Wu Y., Yakar S., Zhao L., Hennighausen L. and LeRoith D. (2002) Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 62: 1030-1035
157. Winkler R., Delacroix L., Bensbaho K., Lambert S., Collette J. and Hodzic D. (1999) IGF-II in primary human colorectal tumors: peptide level, activated promoters, parental imprinting and gene rearrangement. Horm. Metab. Res. 31: 148-154
158. Renehan A. G., Jones J., Rotten C. S., Shalet S. M. and O'Dwyer S. T. (2000) Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br. J. Cancer 83: 1344-1350
159. Hassan A. B. and Macaulay V. M. (2002) The insulin-like growth factor system as a therapeutic target in colorectal cancer. Ann. Oncol. 13: 349-356
160. Karnes W. E. Jr, Walsh J. H., Wu S. V, Kim R. S., Martin M. G., Wong H. C. et al. (1992) Autonomous proliferation of colon cancer cells that coexpress transforming growth factor alpha and its receptor. Variable effects of receptor-blocking antibody. Gastroenterology 102: 474-485
161. Akagi K., Ikeda Y., Miyazaki M., Abe T., Kinoshita J., Maehara Y et al. (2000) Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br. J. Cancer 83: 887-891
162. Finley G. G., Koski R. A., Melhem M. F., Pipas J. M. and Meisler A. I. (1993) Expression of the gastrin gene in the normal human colon and colorectal adenocarcinoma. Cancer Res. 53: 2919-2926
163. Watson S. A., Clifford T., Sykes R. E., Robinson E. and Steele R. J. (1995) Gastrin sensitivity of primary human colorectal cancer: the effect of gastrin receptor antagonism. Eur. J. Cancer 31 A: 2086-2092
164. Hoosein N. M., Kiener P. A., Curry R. C., Rovati L. C., McGilbra D. K. and Brattain M. G. (1988) Antiproliferative effects of gastrin receptor antagonists and antibodies to gastrin on human colon carcinoma cell lines. Cancer Res. 48: 7179-7183
165. Lamote J. and Willems G. (1988) Stimulating effect of pentagastrin on cancer cell proliferation kinetics in chemically induced colon cancer in rats. Regul. Pept. 20: 1-9
166. Palmer Smith J. and Solomon T. E. (1988) Effects of gastrin, proglumide and somatostatin on growth of human colon cancer. Gastroenterology 95: 1541-1548
167. Palmer Smith J., Wood J. G. and Solomon T. E. (1989) Elevated gastrin levels in patients with colon cancer or adenomatous polyps. Dig. Dis. Sci. 34: 171-174
168. Seitz J. F., Giovannini M., Gouvernet J. and Gauthier A. P. (1991) Elevated serum gastrin levels in patients with colorectal neoplasia. J. Clin. Gastroenterol. 13: 541-555
169. Preston S. R., Woodhouse L. F., Jones-Blackett S., Miller G. V. and Primrose J. N. (1995) High-affinity binding sites for gastrin-releasing peptide on human colorectal cancer tissue but not uninvolved mucosa. Br. J. Cancer 71: 1087-1089
170. Saurin J.-C., Rouault J. P., Abello J., Berger F., Remy L. and Chayvialle J. A. (1999) High gastrin releasing peptide receptor mRNA level is related to tumour dedifferentiation and lymphatic vessel invasion in human colon cancer. Eur. J. Cancer. 35: 125-132
171. Williams B. Y. and Schonbrunn A. (1994) Bombesin receptors in a human duodenal tumor cell line: binding properties and function. Cancer Res. 54: 818-824
172. Carroll R. E., Matkowskyj K. A., Chakrabarti S., McDonald T. J. and Benya R. V. (1999) Aberrant expression of gastrin releasing peptide and its receptor by well differentiated colon cancers in humans. Am. J. Physiol. 276: 655-665
173. Rao P. S., Thakur M. L., Pallela V., Parti R., Reddy K., Li H. et al. (2001) 99mTc labeled VIP analog: evaluation for imaging colorectal cancer. Nucl. Med. Biol. 28: 445-450
174. 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. Br. J. Cancer 78: 1-5
175. Qin Y., Schally A. V. and Willems G. (1991) Somatostatin analogue RC-160 inhibits the growth of transplanted colon cancer in rats. Int. J. Cancer 47: 765-770
176. Qin Y., Van Cauteren M., Osteaux M., Schally A. V. and Willems G. (1992) Inhibitory effect of somatostatin analogue RC-160 on the growth of hepatic metastases of colon cancer in rats: a study with magnetic resonance imaging. Cancer Res. 52: 6025-6030
177. Qin Y., Schally A. V. and Willems G. (1992) Treatment of liver metastases of human colon cancers in nude mice with somatostatin analogue RC-160. Int. J. Cancer 52: 791-796
178. Dy D. Y., Whitehead R. H. and Morris D. L. (1992) SMS 201.995 inhibits in vitro and in vivo growth of human colon cancer. Cancer Res. 52: 917-923
179. Radulovic S., Miller G. and Schally A. V. (1991) Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095). Cancer Res. 51: 6006-6009
180. Radulovic S., Schally A. V., Reile H., Halmos G., Szepeshazi K., Groot K. et al. (1994) Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice. Acta Oncol. 33: 693-701
181. Tesei A., Ricotti L., De Paola F., Casini-Raggi C., Barzanti F., Frassineti G. L. et al. (2000) Lanreotide-induced modulation of 5-fluorouracil or mitomycin C cytotoxicity in human colon cancer cell lines: a preclinical study. J. Chemother. 12: 421-430
182. Szepeshazi K., Schally A. V., Halmos G., Armatis P., Hebert F., Sun B. et al. (2002) Targeted cytotoxic somatostatin analogue AN-238 inhibits somatostatin receptor-positive experimental colon cancers independently of their p53 status. Cancer Res. 62: 781-788
183. Chayvialle J. A., Miyata M., Descos F., Rayford P. L. and Thompson J. C. (1982) Physiological observations on vasoactive intestinal peptides in the digestive tract. In: Vasoactive Intestinal Peptide, Raven Press. Said S. I. (ed.) New York, pp. 447-456
184. Hoosein N.M., Black B. E., Brattain D. E. and Brattain M. G. (1989) Promotion of differentiation in human colon carcinoma cells by vasoactive intestinal polypeptide. Regul. Pept. 24: 15-26
185. Szepeshazi K., Schally A. V., Groot K., Armatis P., Halmos G., Hebert F. et al. (2000) Antagonists of growth hormone-releasing hormone (GH-RH) decrease IGF-II production of HT-29 human colon cancer cells and inhibit tumour growth. Br. J. Cancer 82: 1724-1731
186. Pollak M. N., Polychronakos C. and Guyda H. (1989) Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res. 9: 889-892
187. Goldberg R. M., Moertel C. G., Wieand H. S., Krook J. E., Schutt A. J., Veeder M. H. et al. (1995) A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. Cancer 76: 961-966
188. Hejna M., Schmidinger M. and Raderer M. (2002) The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann. Oncol. 13: 653-668
189. Di Leo A., Bajetta E., Ferrari L., Biganzoli L., Mariani L., Carnaghi C. et al. (1996) A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma. Cancer 78: 35-42
190. Cascinu S., Catalano V., Giordani P., Baldelli A. M., Agostinelli R. and Catalano G. (2001) Gastrointestinal cancer refractory to chemotherapy: a role for octreotide? Chemotherapy 47 (Suppl. 2): 127-133
191. Hurwitz H., Fehrenbacher L., Cartwright T., Hainsworth J., Heim W., Berlin J. et al. (2003) Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Abstract no. 3646, American Society of Clinical Oncology (ASCO) Meeting
192. Burch P. A., Block M., Schroeder G., Kugler J. W., Sargent D. J., Braich T. A. et al. (2000) Phase in evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer. Clin. Cancer Res. 6: 3486-3492
193. Risch H. A. (2003) Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J. Natl. Cancer Inst. 95: 948-960
194. Silverman D. T., Dunn J. A., Hoover R. N., Schiffman M., Lillemoe K. D., Schoenberg J. B. et al. (1994) Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J. Natl. Cancer Inst. 86: 1510-1516
195. Comaru-Schally A. M. and Schally A. V. (1990) LHRH agonists as adjuncts to somatostatin analogs in the treatment of pancreatic cancer. In: GnRH Analogues in Cancer and Human Reproduction, vol. III, Benign and Malignant Tumors, pp. 203-210, Vickery B. H. and Lunenfeld B. (eds), Kluwer, Boston
196. Warshaw A. L. and Fernandez-del Castillo C. (1992) Pancreatic carcinoma. N. Engl. J. Med. 326: 455-465
197. Gudjonsson B. (1987) Cancer of the pancreas; 50 years of surgery. Cancer 60: 2284-2303
198. Bardeesy N. and DePinho R. A. (2002) Pancreatic cancer biology and genetics. Nat. Rev. Cancer 2: 897-909
199. Friess H., Büchler M. W., Beglinger C., Weber A., Kunz J., Fritsch K. et al. (1993) Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 8: 540-545
200. Kelly D. M. and Benjamin I. S. (1995) Pancreatic carcinoma. Ann. Oncol. 6: 19-28
201. Harris J. and Bruckner H. (2001) Adjuvant and neoadjuvant therapies of pancreatic cancer: a review. Int. J. Pancreatol. 29: 1-7
202. Cullinan S., Moertel C. G., Wieand H. S., Schutt A. J., Krook J. E., Foley J. F. et al. (1990) A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin and cisplatin. Cancer 65: 2207-2212
203. Poston G. J., Gillespie J. and Guillou P. J. (1991) Biology of pancreatic cancer. Gut 32: 800-812
204. Reddy S. A. (2001) Signaling pathways in pancreatic cancer. Cancer J. 7: 274-86
205. Fisher W. E., Muscarella P., Boros L. G. and Schirmer W. J. (1998) Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma. Int. J. Pancreatol. 24: 169-180
206. Pour P. M. and Kazakoff K. (1996) Stimulation of islet cell proliferation enhances pancreatic ductal carcinogenesis in the hamster model. Am. J. Pathol. 149: 1017-1025
207. Herrington M. K. and Adrian T. E. (1995) On the role of cholecystokinin in pancreatic cancer. Int. J. Pancreatol. 17: 121-138
208. Casper E. S. (1993) Pancreatic cancer: how can we progress? Eur. J. Cancer 29 A: 171-172
209. Bergmann U., Funatomi H., Yokoyama M., Beger H. G. and Korc M. (1995) Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 55: 2007-2011
210. Bergmann U., Funatomi H., Kornmann M., Ishiwata T., Beger H. G. and Korc M. (1996) Insulin-like growth factor II activates mitogenic signaling in pancreatic cells via IRS-1: in vivo evidence for an islet-cancer cell axis. Int. J. Oncol. 9: 487-492
211. Liebow C., Hierowski M. and duSapin K. (1986) Hormonal control of pancreatic cancer growth. Pancreas 1: 44-48
212. Chester J. F., Gaissert H. A., Ross J. S. and Malt R. A. (1986) Pancreatic cancer in the Syrian hamster induced by N-nitroso-bis(2-oxopropyl)- amine: cocarcinogenic effect of epidermal growth factor. Cancer Res. 46: 2954-2957
213. Smith J. J., Derynck R. and Korc M. (1987) Production of transforming growth factor α in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc. Natl. Acad. Sci. USA 84: 7567-7570
214. Murphy L. O., Cluck M. W., Lovas S., Ötvös F., Murphy R. F., Schally A. V. et al. (2001) Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions. Br. J. Cancer 84: 926-935
215. Korc M. (1998) Role of growth factors in pancreatic cancer. Surg. Oncol. Clin. N. Am. 7: 25-41
216. Overholser J. P., Prewett M. C., Hooper A. T., Waksal H. W. and Hicklin D. J. (2000) Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89: 74-82
217. Bruns C. J., Solorzano C. C., Harbison M. T., Ozawa S., Tsan R., Fan D. et al. (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60: 2926-2935
218. Xiong H. Q. and Abbruzzese J. L. (2002) Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin. Oncol. 29 (Suppl. 14): 31-37
219. Kornmann M., Beger H. G. and Korc M. (1998) Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas 17: 169-175
220. Yokoyama M., Yamanaka Y., Friess H., Buchler M. and Korc M. (1994) p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res. 14: 2477-2484
221. Zhu Z., Kleeff J., Kayed H., Wang L., Korc M., Buchler M. W. et al. (2002) Nerve growth factor and enhancement of proliferation, invasion, and tumorigenicity of pancreatic cancer cells. Mol. Carcinogenesis 35: 138-147
222. Johnson L. R. (1981) Effects of gastrointestinal hormones on pancreatic growth. Cancer 47: 1640-1645
223. Dembinski A. B. and Johnson L. R. (1979) Growth of pancreas and gastrointestinal mucosa in antrectomized and gastrin-treated rats. Endocrinology 105: 769-773
224. Dembinski A. B. and Johnson L. R. (1980) Stimulation of pancreatic growth by secretin, caerulein, and pentagastrin. Endocrinology 106: 323-328
225. Solomon T. E., Petersen H., Elashoff J. and Grossman M. I. (1978) Interaction of caerulein and secretin on pancreatic size and composition in rat. Am. J. Physiol. 235: E714-E719
226. Bell R. H. Jr, Kuhlmann E. T., Jensen R. T. and Longnecker D. S. (1992) Overexpression of cholecystokinin receptors in azaserine-induced neoplasms of the rat pancreas. Cancer Res. 52: 3295-3299
227. Reubi J. C., Waser B., Gugger M., Friess H., Kleeff J., Kayed H. et al. (2003) Distribution of CCK1 and CCK2 receptors in normal and diseased human pancreatic tissue. Gastroenterology 125: 98-106
228. Zhou W., Povoski S. P., Longnecker D. S. and Bell R. H. Jr (1992) Novel expression of gastrin (cholecystokinin-B) receptors in azaserine-induced rat pancreatic carcinoma: receptor determination and characterization. Cancer Res. 52: 6905-6911
229. Seva C., Scemama J. L., Bastie M. J., Pradayrol L. and Vaysse N. (1990) Lorglumide and loxiglumide inhibit gastrin-stimulated DNA synthesis in a rat tumoral acinar pancreatic cell line (AR42J). Cancer Res. 50: 5829-5833
230. Goetze J. P., Nielsen F. C., Burcharth F. and Rehfeld J. F. (2000) Closing the gastrin loop in pancreatic carcinoma: coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. Cancer 88: 2487-2494
231. Jiang S., Kopras E., McMichael M., Bell R. H. Jr and Ulrich C. D. 2nd (1997) Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells. Cancer Res. 57: 1475-1480
232. Abbruzzese J. L., Gholson C. F., Daugherty K., Larson E., DuBrow R., Berlin R. et al. (1992) A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. Pancreas 7: 165-171
233. Theve N. O., Pousette A. and Carlstrom K (1983) Adenocarcinoma of the pancreas-a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol. 9: 193-197
234. Greenway B. A. (1987) Carcinoma of the exocrine pancreas: a sex hormone responsive tumour? Br. J. Surg. 74: 441-442
235. Wenger F. A., Kilian M., Mautsch I., Jacobi C. A., Schimke I., Saul G. J. et al. (2000) Influence of octreotide and tamoxifen on tumor growth and liver metastasis in N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian hamsters. Horm. Res. 54: 74-77
236. Szepeshazi K., Lapis K. and Schally A. V. (1991) Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters. Int. J. Cancer 49: 260-266
237. Redding T. W. and Schally A. V. (1984) Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc. Natl. Acad. Sci. USA 81: 248-252
238. 6)LH-RH on tumor-bearing Syrian golden hamsters. Receptor 4: 201-207
239. Viguerie N., Esteve J. P., Susini C., Vaysse N. and Ribet A. (1987) Processing of receptor-bound somatostatin: internalization and degradation by pancreatic acini. Am J Physiol. 252: G535-G542
240. Hierowski M. T., Liebow C., du Sapin K. and Schally A. V. (1985) Stimulation by somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa-2 cell line. FEBS Lett. 179: 252-256
241. Paz-Bouza J. I., Redding T. W. and Schally A. V. (1987) Treatment of nitrosamine-induced pancreatic tumors in hamsters with analogs of somatostatin and luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 84: 1112-1116
242. Szende B., Srkalovic G., Schally A. V., Lapis K. and Groot K. (1990) Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression. Cancer 65: 2279-2290
243. Wenger F. A., Kilian M., Jacobi C. A., Mautsch I., Peter F. J., Guski H. et al. (2001) Effects of octreotide on liver metastasis and intrametastatic lipid peroxidation in experimental pancreatic cancer. Oncology 60: 282-288
244. Radulovic S., Comaru-Schally A. M., Milovanovic S. and Schally A. V. (1993) Somatostatin analogue RC-160 and LH-RH antagonist SB-75 inhibit growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Pancreas 8: 88-97
245. Qin Y., Ertl T., Groot K., Horvath J., Cai R. Z. and Schally A. V (1995) Somatostatin analog RC-160 inhibits growth of CF-PAC-1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate. Int. J. Cancer 60: 694-700
246. Poston G. J., Townsend C. M. Jr, Rajaraman S., Thompson J. C. and Singh P. (1990) Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. Pancreas 5: 151-157
247. Weckbecker G., Tolcsvai L., Liu R. and Bruns C. (1992) Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995). Metabolism 41 (Suppl. 2): 99-103
248. Gillespie J., Poston G. J., Schachter M. and Guillou P. J. (1992) Human pancreatic cancer cell lines do not express receptors for somatostatin. Br. J. Cancer 66: 483-487
249. Delesque N., Buscail L., Esteve J. P., Saint-Laurent N., Muller C., Weckbecker G. et al. (1997) sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res. 57: 956-962
250. Vernejoul F., Faure P., Benali N., Calise D., Tiraby G., Pradayrol L. et al. (2002) Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res. 62: 6124-6131
251. Froidevaux S., Eberle A. N., Christe M., Sumanovski L., Heppeler A., Schmitt J. S. et al. (2002) Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int. J. Cancer 98: 930-937
252. Duncan J. R., Stephenson M. T., Wu H. P. and Anderson C. J. (1997) Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res. 57: 659-671
253. Radulovic S., Nagy A., Szoke B. and Schally A. V. (1992) Cytotoxic analog of somatostatin containing methotrexate inhibits growth of MIA PaCa-2 human pancreatic cancer xenografts in nude mice. Cancer Lett. 62: 263-271
254. Szepeshazi K., Schally A. V., Halmos G., Sun B., Hebert F., Csernus B. et al. (2001) Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. Clin. Cancer Res. 7: 2854-2861
255. Benali N., Cordelier P., Calise D., Pages P., Rochaix P., Nagy A. et al. (2000) Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc. Natl. Acad. Sci. USA 97: 9180-9185
256. Upp J. R. Jr, Poston G. J., MacLellan D. G., Townsend C. M. Jr, Barranco S. C. and Thompson J. C. (1988) Mechanisms of the trophic actions of bombesin on the pancreas. Pancreas 3: 193-198
257. Douglas B. R., Woutersen R. A., Jansen J. B., de Jong A. J., Rovati L. C. and Lamers C. B. (1989) Influence of cholecystokinin antagonist on the effects of cholecystokinin and bombesin on azaserine-induced lesions in rat pancreas. Gastroenterology 96: 462-469
258. Hajri A., Balboni G., Koenig M., Garaud J. C. and Damge C. (1992) Gastrin-releasing peptide: in vivo and in vitro growth effects on an acinar pancreatic carcinoma. Cancer Res. 52: 3726-3732
259. Hajri A., Koenig M., Balboni G. and Damge C. (1996) Expression and characterization of gastrin-releasing peptide receptor in normal and cancerous pancreas. Pancreas 12: 25-35
260. Qin Y., Ertl T., Cai R. Z., Halmos G. and Schally A. V. (1994) Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro. Cancer Res. 54: 1035-1041
261. Szepeshazi K., Schally A. V., Cai R. Z., Radulovic S., Milovanovic S. and Szoke B. (1991) Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters. Cancer Res. 51: 5980-5986
262. Szepeshazi K., Schally A. V., Groot K. and Halmos G. (1993) Effect of bombesin, gastrin-releasing peptide (GRP) (14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters. Int. J. Cancer 54: 282-289
263. Qin Y., Ertl T., Cai R. Z., Horvath J. E., Groot K. and Schally A. V. (1995) Antagonists of Bombesin/gastrin-releasing peptide inhibit growth of SW-1990 human pancreatic adenocarcinoma and production of cyclic AMP. Int. J. Cancer 63: 257-262
264. Zachary I., Sinnett-Smith J. W. and Rozengurt E. (1986) Early events elicited by bombesin and structurally related peptides in quiescent Swiss 3T3 cells: I. Activation of protein kinase C and inhibition of epidermal growth factor binding. J. Cell. Biol. 102: 2211-2222
265. Liebow C., Crean D. H., Lee M. T., Kamer A. R., Mang T. S. and Schally A. V. (1994) Synergistic effects of bombesin and epidermal growth factor on cancers. Proc. Natl. Acad. Sci. USA 91: 3804-3808
266. Pandol S. J, Seifert H., Thomas M. W., Rivier J. and Vale W. (1984) Growth hormone-releasing factor stimulates pancreatic enzyme secretion. Science 225: 326-328
267. Szepeshazi K., Schally A. V., Groot K., Armatis P., Hebert F. and Halmos G. (2000) Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumors. Eur. J. Cancer 36: 128-136
268. Gonzalez-Barcena D., Rangel-Garcia N. E., Perez-Sanchez P. L., Gutierrez-Damperio C., Garcia-Carrasco F., Comaru-Schally A. M. et al. (1986) Response to D-Trp-6-LH-RH in advanced adenocarcinoma of pancreas. Lancet 2: 154
269. Gonzalez-Barcena D., Ibarra-Olmos M. A., Garcia-Carrasco E, Gutierrez-Samperio C., Comaru-Schally A. M. and Schally A. V (1989) Influence of D-Trp-6-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed. Pharmacother. 43: 313-317
270. Friess H., Buchler M., Kruger M. and Beger H. G. (1992) Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin. Pancreas 7: 516-521
271. Swarovsky B., Wolf M., Havemann K. and Arnold R. (1993) Tamoxifen or cyproterone acetate in combination with buserelin are ineffective in patients with pancreatic adenocarcinoma. Oncology 50: 226-229
272. Poston G. J. and Schally A. V. (1993) Somatostatin analogs and pancreatic cancer. Int. J. Pancreatol. 14: 64-66
273. Schally A. V., Szepeshazi K., Qin Y., Halmos G., Ertl T., Groot K. et al. (1994) Antitumor effects of analogs of somatostatin and antagonists of bombesin/GRP in experimental models of pancreatic cancer. Int. J. Pancreatol. 16: 246-249
274. Rosenberg L., Barkun A. N., Denis M. H. and Pollak M. (1995) Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 75: 23-28
275. Friess H., Buchler M., Beglinger C., Weber A., Kunz J., Fritsch K. et al. (1993) Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 8: 540-545
276. Sulkowski U., Buchler M., Pederzoli P., Arnold R., Dinse P., Kay A. et al. (1999) A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma. Eur. J. Cancer 35: 1805-1808
277. Fazeny B., Baur M., Prohaska M., Hudec M., Kremnitzer M., Meryn S. et al. (1997) Octreotide combined with goserelin in the therapy of advanced pancreatic cancer-results of a pilot study and review of the literature. J. Cancer Res. Clin. Oncol. 123: 45-52
278. Reubi J. C., Horisberger U., Essed C. E., Jeekel J., Klijn J. G. and Lamberts S. W. (1988) Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology 95: 760-763
279. Klijn J. G., Hoff A. M., Planting A. S., Verweij J., Kok T., Lamberts S. W. et al. (1990) Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Br. J. Cancer 62: 627-630
280. Canobbio L., Boccardo F., Cannata D., Gallotti P. and Epis R. (1992) Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. Cancer 69: 648-650
281. Buscail L. (1998) Re: expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer. J. Natl. Cancer Inst. 90: 864-865
282. Fisher W. E., Doran T. A., Muscarella P. II, Boros L. G., Ellison E. C. and Schirmer W. J. (1998) Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer. J. Natl. Cancer Inst. 90: 322-324
283. 111In-pentetreotide. State of the art and perspectives. Q. J. Nucl. Med. 44: 88-95